A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers.

Trial Profile

A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs Everolimus (Primary) ; Topotecan
  • Indications Endometrial cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Dec 2008 Actual start date ( Dec 2008) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Planned end date changed from 1 Oct 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top